Trial cohorts report clinical remission (cessation of active symptoms) in 40–65% of stem cell recipients at 12 weeks, with endoscopic healing in a smaller subset (~30–40%). Comparison to biologic therapy remission rates (50–60% at 12 weeks) suggests marginal advantage, if any. Real-world outcomes from uncontrolled private clinics report higher success claims (70–80%), though robust outcome data are absent. Heterogeneity between trials complicates meta-analysis.
Fourteen registered trials are examining stem cell or MSC-derived approaches in ulcerative colitis populations worldwide. A 2022 phase II study involving 41 UC patients receiving intravenous allogeneic placental MSCs showed clinical remission rates of 61% at week 12, versus 24% in the placebo arm. Endoscopic inflammation scores improved significantly in the treatment group. However, this trial lacked a blinded design, and a subsequent meta-analysis of 9 UC stem cell trials (total n=187) reported heterogeneous outcomes with clinical remission ranging 35–68%. No phase III trial data have been published. Mechanistic studies indicate tumour necrosis factor suppression and regulatory T-cell expansion.
Являюсь ли я кандидатом? → · Ulcerative Colitis: full overview → · Стоимость Язвенный колит → · Cost →
Медицинское рецензирование редакторской командой StemCellAtlas с Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) клиники-партнёра Stem Plus (София) в соответствии с руководствами ISSCR, FDA и EMA. Educational information, not medical advice; figures indicative.
GMP-сертифицированная регенеративная медицина в сердце ЕС — от €3 000–8 000, доля от цен США или Германии. Индивидуальные протоколы для пациентов из 50+ стран.
Бесплатная оценка врача